MX349119B - Vacuna de virus de dengue inactivado. - Google Patents

Vacuna de virus de dengue inactivado.

Info

Publication number
MX349119B
MX349119B MX2013013862A MX2013013862A MX349119B MX 349119 B MX349119 B MX 349119B MX 2013013862 A MX2013013862 A MX 2013013862A MX 2013013862 A MX2013013862 A MX 2013013862A MX 349119 B MX349119 B MX 349119B
Authority
MX
Mexico
Prior art keywords
dengue virus
virus vaccine
inactivated dengue
inactivated
producing
Prior art date
Application number
MX2013013862A
Other languages
English (en)
Spanish (es)
Other versions
MX2013013862A (es
Inventor
Henderickx Veronique
Le Bussy Olivier
Ingrid Lemoine Dominique
Mathot Frédéric
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2013013862A publication Critical patent/MX2013013862A/es
Publication of MX349119B publication Critical patent/MX349119B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2013013862A 2011-05-26 2012-05-25 Vacuna de virus de dengue inactivado. MX349119B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490205P 2011-05-26 2011-05-26
US201161570966P 2011-12-15 2011-12-15
PCT/EP2012/059879 WO2012160199A1 (en) 2011-05-26 2012-05-25 Inactivated dengue virus vaccine

Publications (2)

Publication Number Publication Date
MX2013013862A MX2013013862A (es) 2014-01-23
MX349119B true MX349119B (es) 2017-07-12

Family

ID=46148894

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013862A MX349119B (es) 2011-05-26 2012-05-25 Vacuna de virus de dengue inactivado.

Country Status (16)

Country Link
US (1) US20140112953A1 (cg-RX-API-DMAC7.html)
EP (1) EP2714076A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014515367A (cg-RX-API-DMAC7.html)
KR (1) KR20140033171A (cg-RX-API-DMAC7.html)
CN (2) CN107050445A (cg-RX-API-DMAC7.html)
AU (2) AU2012260807B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030236A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837145A1 (cg-RX-API-DMAC7.html)
CO (1) CO6811814A2 (cg-RX-API-DMAC7.html)
EA (1) EA201391515A1 (cg-RX-API-DMAC7.html)
IL (1) IL229307A0 (cg-RX-API-DMAC7.html)
MX (1) MX349119B (cg-RX-API-DMAC7.html)
PE (1) PE20140646A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502442A1 (cg-RX-API-DMAC7.html)
SG (1) SG194950A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012160199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207936B1 (en) 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
EP3316897A4 (en) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
US10765727B2 (en) 2015-09-26 2020-09-08 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BE1024160A9 (fr) * 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
CN107140625A (zh) * 2017-06-14 2017-09-08 中国海洋大学 一种利用植物油制备石墨烯薄膜的方法
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN111526885A (zh) 2017-11-03 2020-08-11 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
CA3084605A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Method for inactivating zika virus and related methods
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
AU2020403013A1 (en) * 2019-12-11 2022-06-02 Ne1 Inc. Personalized tumor vaccine and use thereof for cancer immunotherapy
US20240076631A2 (en) * 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用
CN115531529A (zh) * 2022-09-16 2022-12-30 大连理工大学 一种冻干保护剂在含铝佐剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254873B1 (en) * 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
MXPA03002890A (es) * 2000-10-02 2004-12-03 Glaxosmithkline Biolog Sa Preparacion de virus con envolvente dividido.
HUE051878T2 (hu) * 2003-02-10 2021-03-29 Biogen Ma Inc Immunglobulin készítmény és annak elõállítási módszere
EP2811027A1 (en) * 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
DK2144998T3 (en) * 2007-04-06 2017-04-10 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
EP2337847B1 (en) * 2008-09-29 2015-12-02 Cadila Pharmaceuticals Ltd. Vaccine adjuvants
PE20110992A1 (es) * 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
US9005633B2 (en) * 2009-07-17 2015-04-14 The United States Of America As Represented By The Secretary Of The Navy. Psoralen-inactivated viral vaccine and method of preparation
US8557253B2 (en) * 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine

Also Published As

Publication number Publication date
CA2837145A1 (en) 2012-11-29
AU2016210743A1 (en) 2016-08-25
EA201391515A1 (ru) 2014-05-30
BR112013030236A2 (pt) 2016-12-06
CO6811814A2 (es) 2013-12-16
CN103619349A (zh) 2014-03-05
KR20140033171A (ko) 2014-03-17
JP2014515367A (ja) 2014-06-30
US20140112953A1 (en) 2014-04-24
PH12013502442A1 (en) 2018-03-21
IL229307A0 (en) 2014-01-30
WO2012160199A1 (en) 2012-11-29
CN107050445A (zh) 2017-08-18
AU2012260807B2 (en) 2016-05-12
EP2714076A1 (en) 2014-04-09
MX2013013862A (es) 2014-01-23
PE20140646A1 (es) 2014-05-29
SG194950A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
PH12013502442A1 (en) Inactivated dengue virus vaccine
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
EP4349404A3 (en) Respiratory virus vaccines
CY1116835T1 (el) Νεο ευρωπαϊκο στελεχος toy prrsv
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
PH12018501602A1 (en) Subunit immersion vaccines for fish
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
MY197851A (en) Antibody formulations
PH12015501482B1 (en) Nasal influenza vaccine composition
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MY197723A (en) Vaccine compositions for the prevention of dengue virus infection
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2016014937A (es) Composiciones para el cuidado bucal que tienen estabilidad mejorada.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
GB201017519D0 (en) Vaccines
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX385188B (es) Vacuna de rinitis equina.
MX350283B (es) Virus recombinantes de influenza porcina y usos del mismo.

Legal Events

Date Code Title Description
FG Grant or registration